Search

Your search keyword '"Angelats L"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Angelats L" Remove constraint Author: "Angelats L" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
26 results on '"Angelats L"'

Search Results

1. Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report

2. 268P Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence.

4. 125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors

6. 92P First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)

7. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)

19. 141P Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p).

20. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.

21. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.

22. SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

23. Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.

24. Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.

25. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.

26. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.

Catalog

Books, media, physical & digital resources